Quick answer: what is Eloralintide?
Eloralintide (LY3841136) is Eli Lilly's investigational selective amylin receptor agonist for obesity.
New to peptides? Start with what are peptides? and how do peptides work?
Quick facts
- Class
- Selective amylin receptor agonist
- Maker
- Eli Lilly
- Studied for
- Chronic weight management
- Dosing
- Once weekly (investigational)
- Status
- Phase 2 complete; advancing to Phase 3; not approved
- Maker
- Eli Lilly
- Mechanism
- Selective amylin receptor agonist
- Status
- Phase 2 complete; advancing to Phase 3
Key takeaways
- In a 48-week Phase 2 trial it produced up to about 20% weight loss versus roughly 0.4% on placebo.
- It is being studied both on its own and combined with tirzepatide, and is advancing to Phase 3.
- It is not approved; products sold under its name would be unregulated research material.
Overview
Eloralintide is a long-acting, selective amylin receptor agonist developed by Eli Lilly for weight management. Like petrelintide, it belongs to the amylin class widely viewed as the next major frontier in obesity treatment after the GLP-1 drugs.[1]
It is being studied both on its own and in combination with Lilly's GLP-1/GIP drug tirzepatide. It is investigational — Phase 2 is complete and it is advancing to Phase 3; it is not approved.
How it works
Eloralintide selectively activates the amylin receptor to promote satiety and reduce food intake, working through a pathway separate from GLP-1.[1] Its selectivity is intended to deliver the appetite-suppressing benefits of amylin signalling while being suitable for combination with incretin drugs — the rationale for testing it alongside tirzepatide.[3]
Clinical evidence
In a 48-week Phase 2 trial published in 2025, eloralintide produced up to roughly 20% weight loss versus about 0.4% on placebo, with a tolerability profile that supported moving into Phase 3.[2] Earlier Phase 1 work established its proof of concept and pharmacology.[3]
These are mid-stage results; large Phase 3 outcome and safety data are not yet available, and no regulator has reviewed the drug.
Safety & status
As with other amylin and incretin therapies, the main reported side effects are gastrointestinal. Full long-term safety awaits Phase 3. Eloralintide is not FDA-approved and is not commercially available; products sold under its name would be unregulated research material. See the weight-loss category and its cousin petrelintide.
Frequently asked questions
What is eloralintide?
Eloralintide (LY3841136) is a long-acting, selective amylin receptor agonist developed by Eli Lilly for weight management. It belongs to the amylin class seen as the next frontier after GLP-1 drugs.
How much weight loss does eloralintide cause?
In a 48-week Phase 2 trial published in 2025, eloralintide produced up to about 20% weight loss versus roughly 0.4% on placebo, supporting its advance to Phase 3.
Is eloralintide FDA-approved?
No. Eloralintide is investigational. Phase 2 is complete and it is advancing to Phase 3 trials; no regulator has reviewed it and it is not commercially available.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. Peer-reviewed study
- Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. Peer-reviewed study
- Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026. Peer-reviewed study